This Viewpoint from US FDA Commissioner Robert Califf discusses existing agency decision support tools for assessing the benefits and risks of medical products under review and the advantages of harmonizing the currently separate frameworks used for evaluating devices and for drugs and biologics.
This Viewpoint describes the history of the Surviving Sepsis Campaign (SSC), the rationale for and results of the January 2017 fourth revision to the Surviving Sepsis Guidelines, and future directions for the SSC.
This JAMA Clinical Guidelines Synopsis summarizes the Surviving Sepsis Campaign’s, Society of Critical Care Medicine’s, and European Society of Intensive Care Medicine’s 2017 guideline on management of sepsis and septic shock.
This study uses data from the Texas Department of State Health Services to determine the association between change in distance to a facility that offers abortion after passage of a state law leading to closure of some facilities and percentage change in the number of abortions between 2012 and 2014.
This Viewpoint discusses the importance of continuing infectious diseases research, even after outbreaks subside and disease progression becomes endemic.
Although US racial and ethnic minorities have higher rates of poor health because of health care inequities, more low-income white individuals are affected because of greater population numbers. This Viewpoint explains that efforts to improve poor outcomes would be more effective if strategies were not based on proportions of race.
This Viewpoint discusses potential threats to public health that arise from provisions of the 2016 21st Century Cures Act that allow drug manufacturers to use surrogate measures of safety and that encourage the US Food and Drug Administration to emphasize speed over science in the drug approval process.